• Publications
  • Influence
A Phase I Study of Ixazomib in Combination with Panobinostat and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
Background: In a pivotal trial addition of panobinostat at 20mg three times a week, two weeks on, one week off, to bortezomib and dexamethasone increased progression-free survival of relapsed orExpand
A phase I/II trial of very low to low-dose continuous azacitidine in combination with standard doses of lenalidomide and low-dose dexamethasone in patients with relapsed or refractory multiple
8584 Background: Azacitidine (AZA) may overcome drug resistance of relapsed or refractory multiple myeloma (RRMM).Continuous administration should maximize epigenetic effects and safety. Methods:Expand
Mature results of MM‐011: A phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory
A previous interim report of MM‐011, the first study that combined lenalidomide with anthracycline‐based chemotherapy followed by lenalidomide maintenance for relapsed and/or refractory multipleExpand
Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis
Introduction Randomized studies have shown that bortezomib (BTZ) can be given weekly via intravenous (IV) route or twice weekly via subcutaneous (SC) route with lower neuropathy risk and no loss ofExpand
Rapid Hematologic and Organ Responses with Daratumumab, Bortezomib and Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis
Introduction: Multi-organ dysfunction remains a major cause of morbidity and mortality with light chain amyloidosis (AL) especially for patients not achieving hematologic complete response. ApprovalExpand
Results of an Upfront Myeloma Carepath Pilot with Response-Adapted Therapy
Background: VRD (bortezomib, lenalidomide, dexamethasone) and Rd (lenalidomide, dexamethasone) are standard regimens for upfront treatment of multiple myeloma (MM). VRD is preferred by many centersExpand
Mature Results of MM011: A Phase I/II Trial of Lenalidomide, Liposomal Doxorubicin, Dexamethasone, and Vincristine, Followed by Lenalidomide Maintenance (DVd-R) for Relapsed or Refractory Multiple
Abstract 1967 Background: An initial report of MM011 described the MTD and promising activity in the first 62 patients (pts) (Baz R et al, Ann Oncol 2006). Here we report complete outcomes of theExpand
Very Low to Low Doses of Continuous Azacitidine in Combination with Standard Doses of Lenalidomide and Low-Dose Dexamethasone (Rd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM):
Abstract 5031 Background: Myeloma inevitably becomes refractory to available agents primarily due to accumulation of genetic and epigenetic mutations in the aberrant clone. The s-phase dependent DNAExpand
Monoclonal gammopathy of undetermined significance: A primary care guide
Monoclonal gammopathy of undetermined significance (MGUS) is commonly diagnosed in outpatients being worked up for an array of clinical concerns. It carries a risk of progression to myeloma and otherExpand